Cardiovascular Risk in Type 2 Diabetic Patients With Asymptomatic Hyperuricemia and Gout

Open access


Aim: To study the differences in cardiovascular risk between type 2 diabetic and non-diabetic patients with asymptomatic hyperuricemia and gout using the Framingham Risk Score (FRS) and complex multimodal ultrasonography.

Patients and methods: A total of 201 patients participated, divided into two groups: 1/ patients with asymptomatic hyperuricemia (n = 52), and 2/ patients with gout (n = 149). FRS was determined as well as ultrasound parameters, independent predictors of cardiovascular risk: left atrial size (LA), intima-media thickness (IMT) and common carotid artery resistive index (CCARI).

Results: The patients in the two groups were age-matched and conventional cardiovascular risk factors were equally distributed. In the asymptomatic hyperuricemia group, 12 patients (23.1%) had diabetes. In this group, there was no difference in FRS between diabetic and non-diabetic individuals. However, diabetic patients had larger LA, thicker intima-media and higher CCARI. In the gout group 18 subjects (12%) had diabetes, but the FRS, LA, IMT and CCARI values were similar among diabetic and non-diabetic patients. Furthermore, when gout subjects were subdivided according to the presence of tophi, we found that the subgroup having gouty tophi and diabetes had larger LA (p = 0.014) compared to those with gouty tophi without diabetes.

Conclusion: In diabetic patients with asymptomatic hyperuricemia and gouty tophi, a more complex approach for estimation of cardiovascular risk is needed. Our work suggests that diabetes and tophi might potentiate their action on the cardiovascular system.

1. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009; 61:885-892.

2. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyper-uricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125(7):679-687.

3. Lai HM, Chen CJ, Su BY, et al. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences. Rheumatology 2012; 51(4):715-20.

4. Carnethon MR, Fortmann SP, Palaniappan L, et al. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003; 158(11):1058-67.

5. Boyle JA, McKiddie M, Buchanan KD, et al. Diabetes mellitus and gout. Blood sugar and plasma insulin responses to oral glucose in normal weight, overweight, and gouty patients. 1969; Annals of the Rheumatic Diseases; 28(4):374-8.

6. Niskanen L, Laaksonen DE, Lindstrom J, et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care; 29(3):709-11.

7. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 2008; 47(10):1567-10.

8. Kim SC, Solomon DH. Risk of incident atrial fibrillation in gout: a cohort study. Ann Rheum Dis. 2016; 75(8):1473-8.

9. Rho YH, Lu N, Peloquin CE et al. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016; 75(1):91-5.

10. Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional Association between Diabetes and Gout: the Singapore Chinese Health Study. Scientific reports. 2016 May 10;6:25766. PubMed PMID: 27161168. Pubmed Central PMCID: 4861921.

11. Lanaspa MA, Sanchez-Lozada LG, Choi YJ et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287(48):40732-44.

12. Pontremoli R The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies, Current Medical Research and Opinion, 2017,33:sup3, 27-32.

13. Kizer JR, Bella JN, Palmieri V et al. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: The Strong Heart Study (SHS). Am Heart J. 2006; 151(2):412-418.

14. Staub D, Meyerhans A, Bundi B, et al. Prediction of cardiovascular morbidity and mortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness. Stroke 2006; 37:800-805.

15. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20(3):895-900.

16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.

17. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39.

18. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266.

19. Heine GH, Gerhart MK, Ulrich C, et al. Renal Doppler resistance indices are associated with systemic atherosclerosis in kidney transplant recipients. Kidney Int 2005; 68:878-885.

20. Lang RM, Beirig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.

21. Dalbeth N, Pool B, Gamble GD, et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 2010, 62(5):1549-1556.

22. Jørgensen PT, Jensen MT, Mogelvang R, et al. Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. Diabetes & Vascular Disease Research 2016, 13(5) 321-330.

23. Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther 2018;8(1):47-56.

24. Lin JC, Lin CL, Chen MC, et al. Gout, not hyperuricemia alone, impairs left ventricular diastolic function. Arthritis Res Ther. 2015; 17: 323.

25. Kiechl S, Willeit J. The natural course of atherosclerosis. Part 1: incidence and progression. Arterioscler Thromb Vasc Biol. 1999;19(6):1484-1490.

26. Zhang L, Yin JK, Duan YY, et al. Evaluation of carotid artery elasticity changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014; 13: 39.

27. Cippoli JA, Ferreira-Sae MC, Martins RP et al. Relationship between serum uric acid and internal carotid resistive index in hypertensive women: a cross-sectional study. BMC Cardiovascular Disorders. 2012;12:52.

28. Çukurova S, Pamuk ÖN, Ünlü E, et al. Subclinical atherosclerosis in gouty arthritis patients: a comparative study. Rheumatol Int. 2012; 32(6):1769-73.

29. Montalcini T, Gorgone G, Gazzaruso C, et al. Relation between serum uric acid and carotid intima-meida thickness in healthy postmenopausal women. Intern Emerg Med. 2007; 2(1):19-23.

30. Tavil Y, Kaya MG, Oktar SO, et al. Uric acid level and its association with intima-media thickness in patients with hypertension. Atherosclerosis. 2008; 197(1):159-163.

31. Miao Z, Yan S, Wang J, et al. Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. Inflamm Res. 2009; 58(10):659-68.

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 102 102 21
PDF Downloads 94 94 13